Stephanie Lau

Stephanie Lau

Auto-generated profile, based on publicly available information

Stephanie Lau

Skirball Institute of Biomolecular Medicine, New York University School of Medicine, New York, NY, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Cell Stem Cell
Verified
Journal Article
Closed access
BABeatriz Aranda-Orgilles
Beatriz Aranda-Orgilles
RSRicardo Saldaña-Meyer
Ricardo Saldaña-Meyer
EWEric Wang
Eric Wang
ETEirini Trompouki
Eirini Trompouki
AFAnne Fassl
Anne Fassl
IAIannis Aifantis
Iannis Aifantis

23 February 2012 in Journal of Aerosol Medicine and Pulmonary Drug Delivery
Verified
Journal Article
Closed access
KDKeith T. Diaz
Keith T. Diaz
SSShibu Skaria
Shibu Skaria
KHKeith Harris
Keith Harris
MSMario Solomita
Mario Solomita
SLStephanie Lau
Stephanie Lau
RCRany Condos
Rany Condos
Background: Inhaled interferon-γ aerosol (aINF-γ) may be effective treatment for idiopathic pulmonary fibrosis (IPF). We evaluated safety and delivery of aIFN-γ (100 μg 3 times/week) in 10 IPF patients using the I-neb (Philips Respironics, Parsippany, NJ). Methods: IFN-γ activity in the aerosol was confirmed by viral inhibition. Ten patients with an average age of 68 diagnosed with IPF (American Thoracic Society/European Respiratory Society consensus guidelines) were enrolled. In vivo deposition was measured via a gamma camera. The nebulizer recorded patient adherence to therapy. Pulmonary function tests [PFTs, forced vital capacity (FVC), total lung capacity (TLC), diffusing capacity for carbon monoxide (DLCO)] and the 6-min walk test were measured at baseline, and every 12–14 weeks for 80 weeks. Bronchoalveolar lavage (BAL) of the middle lobe was performed at baseline and 28 weeks. BAL and plasma samples were analyzed for chemokines and cytokines, including INF-γ. Results: All 10 patients tolerated 80 weeks of inhaled IFN-γ well, with no systemic side effects. True adherence with aerosol treatment averaged 96.7±4.81% (±SEM). In vivo lung deposition averaged 65.4±4.8μg and oropharyngeal deposition 12.6±3.0 μg. BAL IFN-γ increased 60-fold and profibrotic cytokines (FGP-2, Flt-3 ligand, IL-5) were significantly decreased; IFN-γ plasma levels were unchanged. PFTs showed minimal change in FVC. Post hoc analysis indicated that the slope of decline in TLC and DLCO reversed after beginning therapy. The 6-min walk was unchanged. Conclusions: IFN-γ is safe in IPF and can be effectively delivered to lung parenchyma. PFTs remained stable throughout the trial. Reversal of pretherapy PFT decline may define an end-point for future clinical trials.

1 May 2009 in Journal of Occupational and Environmental Medicine
Verified
Journal Article
Closed access
JRJoan Reibman
Joan Reibman
MLMengling Liu
Mengling Liu
QCQinyi Cheng
Qinyi Cheng
SLSybille Liautaud
Sybille Liautaud
LRLinda Rogers
Linda Rogers
WRWilliam Rom
William Rom
Objective: To describe physical symptoms in those local residents, local workers, and cleanup workers who were enrolled in a treatment program and had reported symptoms and exposure to the dust, gas, and fumes released with the destruction of the World Trade Center (WTC) on September 11, 2001. Methods: Symptomatic individuals underwent standardized evaluation and subsequent treatment. Results: One thousand eight hundred ninety-eight individuals participated in the WTC Environmental Health Center between September 2005 and May 2008. Upper and lower respiratory symptoms that began after September 11, 2001 and persisted at the time of examination were common in each exposure population. Many (31%) had spirometry measurements below the lower limit of normal. Conclusions: Residents and local workers as well as those with work-associated exposure to WTC dust have new and persistent respiratory symptoms with lung function abnormalities 5 or more years after the WTC destruction.

10 February 2020 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
SLStephanie Lau
Stephanie Lau
AFAnna Feitzinger
Anna Feitzinger
GVGayatri Venkiteswaran
Gayatri Venkiteswaran
JWJohn Wang
John Wang
SLStephen W. Lewellis
Stephen W. Lewellis
HKHolger Knaut
Holger Knaut

1 September 2018 in Developmental Cell
Verified
Journal Article
Closed access
JWJohn Wang
John Wang
YYYandong Yin
Yandong Yin
SLStephanie Lau
Stephanie Lau
JSJagadish Sankaran
Jagadish Sankaran
EREli Rothenberg
Eli Rothenberg
HKHolger Knaut
Holger Knaut

19 April 2019 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
GPGesa E. A. Pust
Gesa E. A. Pust
JPJana Pöttgen
Jana Pöttgen
JRJennifer Randerath
Jennifer Randerath
SLStephanie Lau
Stephanie Lau
Christoph HeesenChristoph Heesen
Christoph Heesen
IPIris-Katharina Penner
Iris-Katharina Penner